HMN-214 - 10mM in DMSO , CAS No.173529-46-9

CAS: 173529-46-9 Cat. No.: H409194 Formula: C₂₂H₂₀N₂O₅S Molecular Weight: 424.48

GRADE & PURITY 10mM in DMSO

Synonyms

Acetamide, N-[(4-methoxyphenyl)sulfonyl]-N-[2-[(1E)-2-(1-oxido-4-pyridinyl)ethenyl]phenyl]-

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Overview

Information

HMN-214 is a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.
In vitro

HMN-214 is an oral prodrug that is rapidly converted to HMN-176. The in vitro data of HMN-214 are scarce. However, HMN-176, active metabolite of HMN-214, shows potent and broad-spectrumanti-tumor activity against various cancer cells, including HeLa, PC-3, DU-145, MIAPaCa-2, U937, MCF-7, A549, and WiDr, with a mean IC50 value of 118 nM. HMN-176 is also cytotoxic to drug-resistant human and murine cell lines, including P388/CDDP, P388/VCR, K2/CDDP, and K2/VP-16, with IC50 values ranging from 143 nM–265 nM. In HeLa cells, HMN-176 (3 μM) blocks cell cycle at G2/M phase. In Doxorubicin-resistant K2/ARS cells, HMN-176 inhibits cell growth with an IC50 value of 2 μM. HMN-176 (3 μM) down-regulates the expression of the multidrug resistance gene (MDR1), due to the disturbance of NF-Y transcription factor binding to the MDR1 promoter. In human RPE1 and CFPAC-1 cells, HMN-176 (2.5 μM) delays satisfaction of the spindle assembly checkpoint. HMN-176 (250 nM–2.5 μM) inhibits meiotic spindle assembly and aster formationin Spisula oocytes. HMN-176 (2.5 μM) also inhibits aster microtubule formation from human centrosomes. These results indicate that the anti-tumor activity of HMN-176 is at least partially via disrupting centrosome-mediated MT assembly during mitosis.

In vivo

HMN-214 is an oral pro-drug of HMN-176 with improved oral absorption. HMN-214 (30 mg/kg) triggers no obvious neurotoxicity in mice. In mouse xenograft model of PC-3, A549, and WiDr cells, HMN-214 (10 mg/kg–20 mg/kg) inhibits tumor growth. In nude mice model bearing multidrug-resistant KB-A.1 cells, HMN-214 (10 mg/kg–20 mg/kg) significantly suppresses MDR1 mRNA expression.
Cell Data

cell lines：

Concentrations：0–10 μM, dissolved in DMSO

Incubation Time：72 hours

Powder Purity:≥99%

Specifications

Synonyms

Acetamide, N-[(4-methoxyphenyl)sulfonyl]-N-[2-[(1E)-2-(1-oxido-4-pyridinyl)ethenyl]phenyl]-

Specifications & Purity

10mM in DMSO

Biochemical and Physiological Mechanisms

HMN-214 is a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

This product requires cold chain shipping. Ground and other economy services are not available.

Action Type

INHIBITOR

Names and Identifiers

Isomeric SMILES

CC(=O)N(C1=CC=CC=C1/C=C/C2=CC=[N+](C=C2)[O-])S(=O)(=O)C3=CC=C(C=C3)OC

Molecular Weight

424.48

Reaxy-Rn

39968105

Reaxys-RN_link_address

https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=39968105&ln=

Chemical and Physical Properties

• Solubility: Solubility (25°C) In vitro DMSO: 24 mg/mL (99.3 mM); Ethanol: 2 mg/mL (8.27 mM); Water: Insoluble

Application Protocols

No manufacturer-verified application protocols are provided for this item. The following general guidance may assist in planning experiments with small-molecule tool compounds; validate and optimize for your system.

• Stock solution (general): Prepare 10–50 mM in anhydrous DMSO. Vortex and, if necessary, brief sonication to ensure homogeneity. Filter-sterilize through 0.22 µm PTFE only if compatible.
• Cell-based assays (general):
  • Dose range-finding: Start with a broad range (e.g., 0.01–30 µM final) using half-log increments to determine active windows while monitoring cytotoxicity.
  • Exposure: 2–24 h for acute pathway engagement; 24–72 h for phenotypic outcomes. Include vehicle controls at matching DMSO.
  • Readouts: Consider orthogonal assays (e.g., phospho-epitope immunoblotting, cell-cycle profiling by flow cytometry, high-content imaging).
• Biochemical assays (general):
  • Maintain low detergent concentrations; confirm DMSO tolerance of the enzymatic system.
  • Include counter-screens to assess assay interference (aggregation, redox cycling, fluorescence quenching/enhancement).
• Data quality: Use randomized plate layouts, interleaved controls, and replicate wells to mitigate edge effects and drift.

These are generic, non-validated suggestions. No specific dilution factors, positive controls, or validated applications are claimed for this product.

Biological Roles

Context (literature, general): HMN-214 is cited in the literature as a bioactive small molecule used as a tool compound in studies of cell-cycle/mitotic regulation. External sources describe HMN-214 in connection with modulation of serine/threonine kinase pathways involved in mitosis. Specific biochemical targets and binding parameters should be verified from primary literature and your in-house assays.

• Research domain: Chemical biology; cell cycle and mitotic checkpoint investigations; oncology-relevant pathway studies (research context only).
• Typical experimental systems: Human or mammalian cell lines for pathway interrogation, target validation, and mechanism-of-action studies; biochemical kinase panels for profiling (when available from literature/contract labs).
• Assay considerations (general):
  • Titrate concentrations to map phenotypic windows and avoid off-target cytotoxicity.
  • Include time-course sampling to distinguish primary pathway effects from downstream stress responses.
  • Use orthogonal readouts (e.g., phospho-specific immunoblots, high-content imaging) to corroborate pathway engagement.
• Controls: Employ a structurally unrelated tool compound with a similar annotated pathway (as a negative or positive control) to mitigate chemotype biases.

Important

• No medical or clinical claims are made. This product is for research use only. Item-specific target annotations and potencies are not provided in this listing; consult PubChem CID 9888590 and peer-reviewed sources for detailed target biology.

Buffer Applications

This product is not a buffering agent. Buffer preparation guidance is generally not applicable.

• Practical note (general): When diluting DMSO stocks of small-molecule probes into aqueous buffers (e.g., PBS, HEPES-buffered media), ensure the final DMSO content is compatible with your biological system (commonly ≤0.1–1% v/v). Mix thoroughly and consider serum-containing media to mitigate precipitation if the compound is hydrophobic.

For buffer formulation components (Tris, HEPES, phosphate, etc.), please refer to dedicated buffering reagents in our catalog.

Green Alternatives

Green chemistry considerations are not directly applicable to HMN-214 as a bioactive library compound (it is not used as a solvent or commodity reagent). However, the following general practices can reduce environmental impact when handling small-molecule screening compounds:

• Solvent minimization: Use micro-scale stock solutions (e.g., 100–500 µL at 10–50 mM) to reduce DMSO consumption and waste.
• Greener solvent choices for cleaning/processing: Where compatible, replace chlorinated wash solvents with ethanol or isopropanol; employ water-based cleaning where feasible.
• Energy efficiency: Consolidate freeze–thaw/aliquoting sessions to minimize freezer door-open time and thermal cycling.
• Waste management: Segregate DMSO-containing aqueous waste; many facilities require organic waste treatment even at low DMSO percentages.
• Procurement and lifecycle: Plan assay plate maps to minimize over-dispensing; share master plates across teams to reduce duplicate thaw cycles and waste.

Comparison (general)

• DMSO vs DMF as stock solvent: DMSO is generally preferred from a safety and environmental standpoint relative to DMF (which has greater reproductive toxicity concerns, literature). Use DMSO where solubility permits.

These are general sustainability guidelines; they do not change the specifications or recommended storage of this item.

Pharmaceutical Uses

No excipient or pharmacopeial status is claimed for this item. HMN-214 is supplied strictly for research use only.

• Formulation context (laboratory research only): In preclinical assay settings, small-molecule tool compounds are commonly handled as DMSO stock solutions and diluted into assay media. This is not a drug substance or drug product component supplied under GMP.
• Regulatory status: Not a USP/EP/BP grade material; no clinical or diagnostic use is intended or permitted.
• Analytical control (general): If used as an internal standard or control article in nonclinical method development, independently verify identity, purity, and stability; maintain appropriate documentation trails distinct from GMP materials.

For excipients or GMP-grade actives, consult our regulated-materials portfolio.

Physical Properties

Item-specific physicochemical specifications are not provided in this listing.

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• Melting point (literature): Not available in this listing; consult primary databases or the CoA for the supplied lot.
• Boiling point (literature): Not typically reported for bioactive solids; consult databases if needed for modeling.
• Density: Not specified for this item; refer to CoA/Spec Sheet.
• LogP/logD, pKa, refractive index: Not specified for this item; refer to CoA/Spec Sheet. Selected calculated values may be available in cheminformatics databases (literature/computed), but are not specifications for this product.
• Solubility guidance (general, not item-specific): Many library compounds dissolve well in anhydrous DMSO to 10–50 mM stock solutions. Aqueous solubility often improves with co-solvent (e.g., ≤1% DMSO or ethanol) and use of serum-containing media for cell assays. Always confirm solubility and stability experimentally for your system.

Important

• Any numerical values from literature or software are informative only; they are NOT Aladdin specifications. For lot-specific values and acceptance criteria, consult the product CoA/Spec Sheet.

Quality & Grades

• Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.
• Intended use: Research use only (per listing). Not for human or veterinary use, drug, diagnostic, or household purposes.
• What the CoA/Spec Sheet typically includes: identity verification (e.g., HPLC/UPLC purity, MS), batch/lot number, appearance, and storage guidance. Some lots may include NMR or water content by Karl Fischer; consult your specific lot documentation.
• UV/LC suitability: If using for bioassay QC or reference purposes, confirm UV cutoff and LC baseline behavior with your instrument; low-UV absorbance solvents and clean glassware are recommended. Item-specific UV data: Not specified for this item; refer to CoA/Spec Sheet.
• Stabilizers: None stated in this listing. If a stabilizer or salt form is present, it will be indicated on the CoA/Spec Sheet.
• Compliance: This catalog entry belongs to a small-molecule/compound library category; no pharmacopeial grade is claimed.

Practical guidance

• Verify identity against an authentic reference (e.g., LC–MS retention and exact mass) before critical studies.
• For screening campaigns, prepare a master vial and dispense single-use aliquots to minimize freeze–thaw cycles and adventitious hydrolysis/oxidation.

Reaction & Applications

This product is a bioactive small-molecule library compound and is not typically employed as a stoichiometric reagent, catalyst, or solvent in synthetic organic reactions.

• Primary use (research): Employed as a tool compound in biochemical and cell-based studies (literature) related to mitotic/cell-cycle pathways. No manufacturer application text is provided in this listing.
• Not applicable to: Grignard chemistry, cross-coupling, reductions/oxidations, or polymerization as a reagent—there is no established use of HMN-214 as a synthetic building block in common reaction families.
• Practical notes for assay applications (general):
  • Prepare fresh DMSO stock solutions and store aliquots at low temperature to mitigate degradation.
  • Validate concentration by UV or quantitative NMR where feasible; adsorption to plastics can lead to apparent potency shifts in high-throughput screening.
  • Include vehicle controls (matching DMSO percentage) in all experiments.

If you require a synthetic intermediate or a functionalized analog for chemistry workflows, consult our catalog for building blocks tailored to your target transformation.

Reaction Conditions

Not applicable. HMN-214 is not offered for use as a reagent or catalyst; no reaction-condition guidance applies.

General laboratory handling for assay preparation (non-reaction use):

• Stock preparation: Dissolve in anhydrous DMSO to a convenient concentration (e.g., 10–50 mM), verifying complete dissolution by visual inspection and, if needed, sonication.
• Working dilutions: Add the DMSO stock to prewarmed buffer/cell culture media under vigorous mixing to avoid local supersaturation and precipitation. Typical final DMSO levels for biological assays are ≤0.1–1% v/v.
• Stability checks: For time-course experiments, verify concentration by LC–MS at t0 and endpoint to monitor degradation/adsorption.

Any numerical reaction temperatures, catalysts, or yields would be irrelevant to this product’s intended use and are therefore not provided.

Safety & Handling

Safety data specific to this item are not included in this listing; handle as a potentially hazardous research chemical.

• GHS classification: Not specified for this item; refer to SDS.
• Signal word / H-statements / pictograms: Not specified for this item; refer to SDS.
• General hazards (general guidance): Many bioactive heterocycles and kinase-pathway probes may present risks of irritation, organ toxicity upon prolonged exposure, or environmental hazard. Avoid inhalation, ingestion, and skin/eye contact.
• Personal protective equipment (PPE): Use lab coat, safety glasses, and appropriate chemically resistant gloves (e.g., disposable nitrile). Work in a certified chemical fume hood or biosafety cabinet as appropriate to your assay.
• Storage incompatibilities: Segregate from strong oxidizers, strong acids/bases, and moisture. Keep tightly closed under inert atmosphere if practical.
• Special risks: Fine powders may be dust-forming; minimize dust generation. For DMSO solutions, note that DMSO increases dermal absorption of solutes—avoid skin contact.
• First-aid overview (general):
  • Inhalation: Move to fresh air; seek medical attention if symptoms persist.
  • Skin/eye contact: Rinse with water for at least 15 minutes; remove contaminated clothing; seek medical attention as needed.
  • Ingestion: Rinse mouth; do not induce vomiting; obtain medical advice.
• Spill response: Absorb with inert material, collect in a chemical waste container; decontaminate area. Prevent release to drains.

Always consult the official SDS for authoritative safety information before use.

Solvent Selection

Since HMN-214 is supplied as a research compound rather than a solvent or reagent, solvent selection relates to preparing stock solutions for screening and in vitro assays.

• Primary solvent (general practice):
  • Anhydrous DMSO is commonly used to prepare 10–50 mM stocks for bioactive small molecules.
• Co-solvent systems (general):
  • For aqueous applications, dilute DMSO stocks into buffers or media to final DMSO ≤0.1–1% v/v, as tolerated by your biological system.
  • Alternative co-solvents include ethanol or DMF in small percentages; confirm compatibility with assay components.
• Polarity/miscibility considerations (general):
  • DMSO is polar aprotic (dielectric ~47, literature) and miscible with water, facilitating serial dilutions.
  • Avoid nonpolar solvents for routine biological assays due to poor aqueous miscibility and potential delivery variability.
• Filtration: If particulates form on dilution, consider gentle warming to ambient temperature and 0.22 µm sterile filtration, provided the compound is filter-stable (verify experimentally).
• Light/air sensitivity: If the structure contains oxidizable motifs (common in drug-like scaffolds), minimize light and oxygen exposure during solution prep (amber vials, nitrogen/argon headspace).

Comparison (general guidance)

• DMSO vs ethanol: DMSO typically offers higher solubility for heteroaromatics; ethanol may be preferable for systems sensitive to DMSO but can reduce solubility. Choose based on assay tolerance and compound behavior.

Storage & Reconstitution

• Storage conditions (as provided): Store at −80°C.
• Shipping: Shipped on dry ice packs + cold packs.
• Stability: Item-specific shelf-life and stability data are not provided; refer to CoA/Spec Sheet. As general practice for small-molecule solids, maintain in a tightly sealed container, protected from light and moisture.

Reconstitution (general guidance; not item-specific)

• Solvent: Anhydrous DMSO is commonly used for bioactive small molecules. Begin with a small volume to achieve the desired concentration (e.g., 10–50 mM), then adjust as needed.
• Technique: Allow vial to equilibrate to room temperature in a desiccator before opening to avoid moisture condensation. Weigh quickly, cap promptly. Vortex and, if needed, sonicate briefly to dissolve.
• Aliquoting: Dispense single-use aliquots into inert, low-bind, amber vials or 96/384-well plates; flush headspace with nitrogen/argon if feasible.
• Storage of solutions: Store DMSO stocks at −20 to −80°C in the dark. Avoid repeated freeze–thaw cycles; thaw on ice and refreeze once only if necessary.
• Aqueous working solutions: Prepare immediately before use; many compounds exhibit limited stability in aqueous media. Discard unused portions after the experiment.

Always consult the current CoA and SDS for lot-specific handling and storage guidance.

Structure & Identity

Brief overview: HMN-214 is listed as a bioactive small molecule in our compound library. Item-specific structural identifiers are not supplied in this listing; see notes below for literature references.

• Product identifiers
  • SKU: H409194
  • Product name: HMN-214
  • CAS: 173529-46-9 (literature)
  • PubChem CID: 9888590 (literature)
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet. (Canonical SMILES available in literature databases; see PubChem CID 9888590.)
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet. (Available in literature databases.)
• Structural features (general/literature): HMN-214 is reported in the literature as a small-molecule tool compound used in cell-cycle/mitotic pathway studies. Public databases (e.g., PubChem, ChEMBL) provide a 2D structure and stereochemical details.
• 2D structure description (literature, general): Descriptions in the literature indicate a drug-like, heteroatom-containing scaffold suitable for dissolution in polar aprotic solvents for bioassays; consult primary database records for exact ring systems, substituent patterns, and stereochemistry.

Notes

• This catalog entry does not include a structure drawing or descriptors; for experimental planning, retrieve the canonical identifiers from PubChem CID 9888590 and verify against the current CoA for this lot.

Synthetic Utility

HMN-214 is not positioned as a synthetic intermediate or reagent in this catalog entry; therefore, conventional synthetic utility (e.g., as a coupling partner, catalyst, or protecting group) is not applicable.

• Retrosynthetic relevance: Not typically used as a building block; the structure (see literature databases) is a finalized bioactive scaffold rather than a modular synthon.
• Derivatization (general): Researchers exploring SAR may consider late-stage diversification of analogous scaffolds via routine transformations (amide coupling, heteroaryl cross-coupling, N-alkylation). Such chemistry pertains to analog development rather than use of HMN-214 itself.

For synthetic projects, we recommend selecting purpose-built building blocks and reagents from our catalog, which include halogenated aromatics, boronates, carboxylic acids, amines, and heterocycles designed for cross-coupling and amide-bond formation.

Target Specificity

Item-specific target annotations are not provided in this listing.

• Target/Pathway: Not specified for this item; refer to CoA/Spec Sheet and primary literature (see PubChem CID 9888590 for external references).
• Mechanism notes (literature, general): Public reports have associated HMN-214 with modulation of mitotic kinase pathways in chemical biology studies. Verify targets, binding constants, and selectivity profiles directly from peer-reviewed sources and by in-house profiling.
• Species reactivity and selectivity panels: Not specified for this item.

For validated reference inhibitors/activators with defined target data and QC documentation, please inquire about our annotated probe collections.